Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2014

Conditions
B-cell Lymphomas
Interventions
DRUG

Oxaliplatin, Prednisolone

"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"

Trial Locations (1)

602-715

Dong-A University Hospital, Busan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Chung-Ang University

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Korea Cancer Center Hospital

OTHER

collaborator

Korea University

OTHER

lead

Dong-A University Hospital

OTHER

NCT01068392 - Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) | Biotech Hunter | Biotech Hunter